Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Brendel

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Journal of Clinical Pharmacology|September 13, 2011
Why should prediction discrepancies be renamed standardized visual predictive check?Emmanuelle Comets, Karl Brendel, France Mentré
Journal of Pharmacokinetics and Pharmacodynamics|July 14, 2025
Using Fisher Information Matrix to predict uncertainty in covariate effects and power to detect their relevance in Non-Linear Mixed Effect Models in pharmacometricsLucie Fayette, Karl Brendel, France Mentré
Pharmaceutical Research|March 17, 2026
Advances and Further Comparison of Software Tools for Fisher Information Matrix-Based Design Evaluation in PharmacometricsLucie Fayette, Karl Brendel, France Mentré
Computer Methods and Programs in Biomedicine|January 25, 2008
Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for REmmanuelle Comets, Karl Brendel, France Mentré
Journal of Pharmacokinetics and Pharmacodynamics|December 25, 2009
Evaluation of different tests based on observations for external model evaluation of population analysesKarl Brendel, Emmanuelle Comets, Céline Laffont, et al.
Pharmaceutical Research|August 15, 2006
Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazideKarl Brendel, Emmanuelle Comets, Céline Laffont, et al.
Clinical Pharmacokinetics|December 6, 2012
Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior informationCyrielle Dumont, France Mentré, Clare Gaynor, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 14, 2015
Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessmentSophie Peigné, François Bouzom, Karl Brendel, et al.
Fundamental & Clinical Pharmacology|May 25, 2005
Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapyKarl Brendel, Mayeule Legrand, Anne-Marie Taburet, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 20, 2026
Population Pharmacokinetics and Pharmacokinetics-Pharmacodynamics Analyses of Elafibranor to Support Dose Selection in Primary Biliary CholangitisQing Xi Ooi, Karl Brendel, Stijn van Beek, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of Clinical Pharmacology|September 13, 2011
Why should prediction discrepancies be renamed standardized visual predictive check?Emmanuelle Comets, Karl Brendel, France Mentré
Journal of Pharmacokinetics and Pharmacodynamics|July 14, 2025
Using Fisher Information Matrix to predict uncertainty in covariate effects and power to detect their relevance in Non-Linear Mixed Effect Models in pharmacometricsLucie Fayette, Karl Brendel, France Mentré
Pharmaceutical Research|March 17, 2026
Advances and Further Comparison of Software Tools for Fisher Information Matrix-Based Design Evaluation in PharmacometricsLucie Fayette, Karl Brendel, France Mentré
Computer Methods and Programs in Biomedicine|January 25, 2008
Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for REmmanuelle Comets, Karl Brendel, France Mentré
Journal of Pharmacokinetics and Pharmacodynamics|December 25, 2009
Evaluation of different tests based on observations for external model evaluation of population analysesKarl Brendel, Emmanuelle Comets, Céline Laffont, et al.
Pharmaceutical Research|August 15, 2006
Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazideKarl Brendel, Emmanuelle Comets, Céline Laffont, et al.
Clinical Pharmacokinetics|December 6, 2012
Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior informationCyrielle Dumont, France Mentré, Clare Gaynor, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 14, 2015
Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessmentSophie Peigné, François Bouzom, Karl Brendel, et al.
Fundamental & Clinical Pharmacology|May 25, 2005
Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapyKarl Brendel, Mayeule Legrand, Anne-Marie Taburet, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 20, 2026
Population Pharmacokinetics and Pharmacokinetics-Pharmacodynamics Analyses of Elafibranor to Support Dose Selection in Primary Biliary CholangitisQing Xi Ooi, Karl Brendel, Stijn van Beek, et al.
Pageof 2